Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people feel noticeably better on Wegovy within the first few weeks once the initial gastrointestinal effects settle — but the first month or two can be rough. Nausea, fatigue and changes to appetite are common, especially after a dose step, and knowing what to do (and what not to do) makes a real difference. Wegovy is a prescription-only medicine containing semaglutide, a GLP-1 receptor agonist licensed in the UK for weight management in adults with a BMI of 30 or above, or 27 or above with a weight-related health condition. A prescriber assesses whether it's right for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide slows the rate at which the stomach empties, and when your dose goes up, that effect intensifies before your body adjusts. The result is nausea, bloating, burping or an unsettled stomach that tends to peak in the first few days after an increase and then gradually eases. For most people it does pass. Clinical trial participants in the STEP programme reported gastrointestinal side effects as most prominent during dose escalation, with many finding they settled at their established maintenance dose.
The most useful quick check: after a dose increase, track how you feel on days two, three and four specifically, rather than judging the whole experience from day one. If things are improving even slightly by day four, that is usually a reassuring pattern. If they are not improving (or are getting worse) that is worth raising with your prescriber rather than pushing through.
One thing many people find helpful is the timing of the injection itself. There is reasonable evidence that injecting in the evening, so the acute peak effect happens overnight, reduces daytime nausea for some. The question of whether evening or morning dosing suits you better is worth exploring with your clinical team, since the answer can vary by person.
Appetite suppression is the point of treatment, but appetite falling off a cliff is not helpful if it means you stop eating properly. The side effects many people struggle with (fatigue, light-headedness, poor concentration) often have less to do with the medicine itself and more to do with not eating enough protein or drinking enough water once hunger cues have quietened down.
A few straightforward adjustments that regularly help: eat smaller amounts more often rather than waiting for hunger to prompt a large meal; prioritise protein at each sitting (eggs, fish, Greek yoghurt, pulses) since protein supports muscle mass and keeps energy steadier; and eat slowly, setting down cutlery between mouthfuls. The stomach empties more slowly on semaglutide, so eating quickly leads to uncomfortable fullness and reflux more easily than it did before.
Fatty food, very rich food and carbonated drinks are frequently reported triggers for nausea and burping on GLP-1 medicines. Avoiding them during the adjustment period, especially around injection day, is practical rather than permanent. The broader question of making semaglutide work as well as possible covers both nutrition and activity in more detail.
The NHS semaglutide medicines page lists the known side effects and includes guidance on when to seek help, a useful reference to keep to hand.
There is a meaningful difference between manageable discomfort and a signal that something needs clinical attention. Mild-to-moderate nausea, a reduced appetite, occasional loose stools, tiredness after a dose increase, these sit within the expected profile for most people and usually improve.
Seek medical help promptly if you experience severe or persistent abdominal pain, particularly if it radiates to your back. In January 2026, the MHRA issued a Drug Safety Update for GLP-1 medicines highlighting acute pancreatitis as an infrequent but serious risk. The symptom pattern (severe stomach pain that does not ease and may reach through to the back, with or without vomiting) warrants same-day contact with a GP or 111, not a "wait and see" approach. You can report unexpected or serious side effects to the MHRA via the Yellow Card scheme.
Signs of dehydration from prolonged vomiting or diarrhoea also need medical attention, since dehydration can affect kidney function. Symptoms of a serious allergic reaction, including swelling of the face or throat or difficulty breathing, need emergency care. Everything else (the garden-variety nausea, the tiredness, the occasional headache) is worth telling your prescriber about at your next review, particularly if it is affecting quality of life, because there are often adjustments that help.
If you are wondering what the general experience of being on Wegovy is like week by week, that page covers the fuller picture of what people typically report.
Fatigue on Wegovy tends to come from two places: the medicine's direct effect in the adjustment period, and the knock-on consequences of eating less, particularly insufficient protein, iron and B vitamins. Both are addressable.
On the nutrition side, keeping a rough mental note of whether you have had a protein source at each meal is a habit that costs nothing and pays off in energy and muscle retention. Hydration is equally overlooked: appetite suppression sometimes extends to thirst cues, and mild dehydration is a surprisingly common cause of persistent tiredness on GLP-1 treatment.
Activity is counterintuitively important. Light movement (a 20-minute walk) can help energy levels more than rest on days when fatigue feels manageable, and strength-based exercise matters for preserving muscle during weight loss. Your prescriber or a dietitian can give personalised guidance on how to structure this alongside treatment.
The fatigue question is also worth raising if it coincides with significant calorie restriction. Treatment is designed to work alongside a reduced-calorie diet, not a very low calorie one; going below around 800 kcal daily without medical supervision is not recommended and compounds the tiredness problem.
For a fuller picture of the treatment itself, the Wegovy treatment overview explains the licensed schedule and how the titration pathway is managed. If you are at the stage of deciding whether Wegovy or another treatment suits you, comparing the options may also be useful before you speak to a prescriber. We also run a Wegovy webinar where our clinicians walk through common questions, including managing side effects during dose escalation, which many people find a useful next step.
At the end of treatment, or if you are thinking about starting, our prescribers are available to review your situation properly. Start your free consultation and a GPhC-registered prescriber will review your answers the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.